CV
Cardiovascular Manifestations of HIV
search
Cardiovascular Manifestations of HIV
, HIV related Cardiovascular Complications, HIV Cardiomyopathy
See Also
HIV Complications
Causes
Infection
Mycobacterium
Nocardia
Cryptococcus neoformans
Histoplasma capsulatum
Aspergillus
Cytomegalovirus
(CMV)
Epstein-Barr Virus
(EBV)
Toxoplasmosis
Causes
Medication adverse effects
Direct cardiotoxicity
Abacavir
(
Ziagen
)
Lopinavir/Ritonavir
(
Kaletra
)
Dyslipidemia or
Lipodystrophy
Protease Inhibitor
s (especially boosted
Protease Inhibitor
s)
Abacavir
Efavirenz
Elvitegravir/
Cobicistat
Findings
Common
Coronary Artery Disease
Longstanding HIV carries a coronary disease equivalent risk similar to
Diabetes Mellitus
HIV-Related Contributing Factors to accelerated atherogenesis
Chronic inflammatory changes
Virus
infected
Macrophage
s
Endothelial dysfunction
CD4 Count
<500 is associated with an increased risk of coronary events (even if it rebounds)
Patients with HIV also have higher rates of
Tobacco Abuse
and
Hypertension
Protease Inhibitor
s also increase dyslipidemia and
Insulin Resistance
References
Frieberg (2013) JAMA Intern Med 173(8):614-22 [PubMed]
Cerebrovascular Disease
Secondary to direct HIV neurotoxicity, opportunistic infections,
Coagulopathy
, chronic inflammation
Patients with HIV also have higher rates of
Tobacco Abuse
,
IVDA
, CAD,
Hypertension
, CKD
Strokes occur at younger ages in HIV patients (esp. with lower
CD4 Count
s, higher viral loads)
D'Ascenzo (2015) J Cardiovasc Med 16(12):839-43 [PubMed]
Dyslipidemia
Obtain lipid panel and
Serum Glucose
at time of HIV diagnosis
Repeat lipid panel and
Glucose
screening at perioidic intervals
Protease Inhibitor
s provoke
Hypertriglyceridemia
and Low HDL
Consider
Statin
s if indicated (based on non-
HIV Infection
guidelines)
Risk of
Statin
-related
Drug Interaction
s with
Protease Inhibitor
s,
NNRTI
agents
Cardiomyopathy
Dilated Cardiomyopathy
(25% advanced HIV)
Left Ventricular Dysfunction
(21% advanced HIV)
Myocardial fibrosis
Present in up to 82% of HIV patients and often asymptomatic
HIV-Related Contributing Factors
Older
Antiretroviral
therapy (AZT)
Kaposi Sarcoma
Opportunistic Infections (
Cryptococcus
,
Toxoplasmosis
)
Malignant infiltration (e.g.
Kaposi Sarcoma
,
Non-Hodgkin Lymphoma
,
Leiomyosarcoma
)
Less common
Myocarditis
Pericardial Effusion
May develop from
HIV Infection
or
Immunocompromised
state
Opportunistic infections (e.g.
Mycobacterium
, HSV, CMC,
Toxoplasmosis
,
Histoplasmosis
,
Cryptococcus
)
Malignancy (
Kaposi Sarcoma
,
Lymphoma
)
Pericarditis
Arrhythmia
s
Autonomic Dysfunction
Rare Conditions
Endocarditis
In addition to
Bacteria
(staph, strep,
HACEK
), fungal organisms (e.g.
Candidiasis
,
Cryptococcus
)
Primary Pulmonary Hypertension
(plexogenic pulmonary arteriopathy)
Symptoms
Most are asymptomatic
Signs
Usually clinically silent
Pericardial Effusion
s (usually sterile) in 25%
Management
See
Cardiomyopathy
In those with
Cardiac Risk Factor
s, avoid agents with cardiotoxicity risk (see above)
Tobacco Cessation
Hyperlipidemia Management
wth
Statin
indicated for 10 year
Cardiac Risk
>5 to 7.5%
Risk of
Statin-Induced Myopathy
Start with low dose
Atorvastatin
(
Lipitor
) 10 mg or
Rosuvastatin
(
Crestor
)
Reference
Baloor (2018) Exam Preparatory Manual for Undergraduates Medicine, Jaypee Brothers, India, p. 242
(2019) Presc Lett 26(8): 46
Mathieu (
Apri
l, 2000) Federal Practitioner, p. 18-20
Swaminathan and Bafuma in Herbert (2017) EM:Rap 17(3): 2
Chu (2017) Am Fam Physician 96(3): 161-9 [PubMed]
Type your search phrase here